drugset / Trial / NCT04627740
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of anti-ALPP chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with ALPP-positive Advanced Solid Tumors.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2025-02-28
- Completion
- 2025-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti ALPP CAR-T cells | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | 20 mg/kg | — |
| Background | Fludarabine | Small molecule | 35 mg/m2 | — |